Extravasation of liposomal doxorubicin induces irritant reaction without vesicant injury

Anticancer Research

Volumn 32, Issue 4, 2012, Pages 1481-1483

  Curtit, Elsa ^a,b,c   Chaigneau, Loïc ^b   Pauchot, Julien ^a,b,c   Nguyen, Thierry ^b   Nerich, Virginie ^a,b,c   Bazan, Fernando ^b   Thiery Vuillemin, Antoine ^a,b,c   Demarchi, Martin ^b   Pivot, Xavier ^a,b,c   Villanueva, Cristian ^b  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^b UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^c INSERM   (France)

Author keywords

Breast cancer; Dexrazoxane; Doxorubicin; Extravasation; Liposomal anthracyclines; Ovarian cancer

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; LIPOSOME; RAZOXANE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CENTRAL VENOUS CATHETER; DRUG EXTRAVASATION; FEMALE; HUMAN; HYPERPIGMENTATION; INJECTION SITE ERYTHEMA; INJECTION SITE EXTRAVASATION; INJECTION SITE PAIN; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; VASCULAR ACCESS DEVICE;

AGED; DOXORUBICIN; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; FEMALE; HUMANS; IRRITANTS; MIDDLE AGED;

EID: 84859998657     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Schrijvers DL: Extravasation: a dreaded complication of chemotherapy. Ann Oncol 14(suppl): 26-30, 2003.
2. Larson DL: What is the appropriate management of tissue extravasation by antitumor agents? Plast Reconstr Surg 75: 397-405, 1985.
3. Giotta F, Lorusso V, Maillol E, Filippelli G, Valerio MR, Caruso M, Verderame F, Latorre A and Colucci G: Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study. Ann Oncol 18(suppl): 66-69, 2007.
4. Barrett-Lee PJ, Dixon JM, Farrell C, Jones A, Leonard R, Murray N, Palmieri C, Plummer CJ, Stanley A and Verril MW: Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol 20: 816-827, 2009.
5. Langer SW, Sehested M, Jensen PB, Buter J and Giaccone G: Dexrazoxane in anthracycline extravasation. J Clin Oncol 18: 3064-3069, 2000.
6. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K, Tkaczuk K, Park YC and Lee LW: Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19: 1444-1454, 2001. (Pubitemid 32202552)
7. Saini A, Berruti A, Sperone P, Bitossi R, Tampellini M, Dogliotti L and Gorzegno G: Recall inflammatory skin reaction after use of pegylated liposomal doxorubicin in site of previous drug extravasation. Lancet Oncol 7: 186-187, 2006. (Pubitemid 43159506)
8. Madhavan S and Northfelt DW: Lack of vesicant injury following extravasation of liposomal doxorubicin. J Natl Cancer Inst 18: 1556-1557, 1995.
9. Lokich J: Doxil extravasation injury: a case report. Ann Oncol 10: 735-736, 1999.
10. Heintel D, Skrabs C, Hauswirth A, Eigenberger K, Einberger C, Raderer M, Raderer M, Sperr WR, Knöbl P, Müllauer L, Uffmann M, Dieckmann K, Gaiger A and Jäger U: Nonpegylated liposomal doxorubicin is highly active in patients with B and T/NK cell lymphomas with cardiac comorbidity or higher age. Ann Hematol 89: 163-169, 2010.